Abstract library

3 results for "Antonijoan Arbós".
#2075 Phase 1 Pharmacokinetic and Pharmacodynamic Study of APOC, a New Controlled Release Formulation (CRF) of 15mg Octreotide Acetate in Healthy Male Volunteers
Introduction: Somatostatin analogues (SSAs) are considered the gold standard for systemic therapy of advanced neuroendocrine tumors (NETs). Octreotide is one of the SSAs most widely used in long-term therapies of NETs. There is increasing evidence that clinical benefits could be obtained with higher SSAs circulating levels but remain unreachable with current products without impacting significantly the quality of life of the patients. APOC is a new injectable controlled release technology containing Octreotide invented and developed by Ascil-Biopharm and designed to cover specifically these clinical unmet needs. It is presented as ready-to-use and can easily be manufactured at selected doses and durations in prefilled syringe.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Rosa Maria Antonijoan Arbós
#2159 Hepatic Steatosis Secondary to Peptide Receptor Radionuclide Therapy with Somatostatin Analogue
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with 177-Lutetium-DOTA-TATE is a therapeutic modality for neuroendocrine tumors. It has some well known side effects, concerning specially the bone marrow (from cytopenias to myelodysplastic syndrome), in addition to mild renal effects. Hepatotoxicity from PRRT is still being studied.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: MD Beatriz Arruda Matheos de Lima
#2195 Audit of a New Nurse-Led Non-Medical Prescribing (NMP) Clinic for Systemic Anti-Cancer Agents (SACTs)
Introduction: The number of people living with cancer in the UK continues to rise with increased demands on specialist cancer care services. NET incidence and prevalence increases alongside this demand. NETs remain a rare cancer with specialist needs. The clinical nurse specialist (CNS) is ideally placed to support these patients. Oncology clinics are increasingly pressured, the need to think of innovative ways of reducing strain whilst maintaining and enhancing the patients experience is important. To address this we set up a nurse-led SACT NMP clinic alongside the oncology clinic to improve patient experience and reduce oncologist clinic review.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Philippa Davies